Global Markets for Insulin Drug and Delivery Technologies

The current report will provide an in-depth look at the insulin drug and delivery technologies market. This report analyzes the market trends of insulin drug and delivery technologies with data from 2021, estimates from 2022, projections of compound annual growth rates through 2027 (forecast period 2022-2027), and regional markets of the insulin drug and delivery technologies. This report will highlight the current and future market potential of insulin drug and delivery technologies along with a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints and opportunities will be covered in the current report. The report also covers market projections for 2026 and market share for key market players.

In this report, the market has been segmented based on device type, insulin type and geographic region. Device types include syringes, insulin pens, insulin pumps, smart pens and others. Insulin types include long-acting, rapid-acting, premixed insulins, intermediate-acting and short-acting.

Geographic regions covered include North America, Europe, Asia-Pacific and the rest of the world (RoW). Individual countries covered include the U.S., Germany, the U.K., Italy, France, Japan, China and India.

Report Includes

24 data tables and 31 additional tables
An up-to-date review of the global markets for insulin drug and delivery technologies
Analyses of the global market trends, with historic market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Highlights of the current state of the insulin drug and delivery industry structure, novel technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
Estimation of the actual market size and market forecast for insulin drug and delivery technologies, and corresponding market share analysis by device type, insulin type, and geographic region
Updated information on the key merger and acquisition deals, partnerships, collaborations and other strategic alliances within the insulin drug and delivery technologies industry
Analysis of market opportunities with a holistic review of the Porter’s Five Forces analysis model considering both the micro and macro environmental factors prevailing in the market
Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
Descriptive company profiles of key manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG

Chapter 1 Introduction

1.1 Insulin Overview
1.2 Diabetes Overview
1.2.1 Disease Symptoms and Risk Factors
1.2.2 Epidemiology and Economic Burden
1.3 Study Goals and Objectives
1.4 Reasons for Doing this Study
1.5 What's New in this Update?
1.6 Scope of Report
1.7 Information Sources
1.8 Methodology
1.9 Geographic Breakdown
1.10 Analyst's Credentials
1.11 Custom Research
1.12 Related Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics

3.1 Market Drivers
3.1.1 Rising Prevalence of Diabetes
3.1.2 Smart Insulin Drug Delivery Technologies
3.1.3 Painless Insulin Drug Delivery Technologies
3.2 Market Restraints
3.2.1 Product Recalls
3.3 Market Opportunities
3.3.1 Inorganic Strategies Amongst Market Players

Chapter 4 Market Overview

4.1 Market Insights
4.1.1 Insulin
4.1.2 Diabetes
4.2 Current Market Trends
4.2.1 Recent Product Introductions
4.2.2 Recent Strategic Alliances
4.3 Future Perspective

Chapter 5 Regulatory Landscape and Reimbursement Scenario

5.1 Regulatory Landscape
5.1.1 U.S. Regulations for Medical Devices
5.1.2 U.S. Drug Regulations
5.1.3 European Regulations for Medical Devices
5.1.4 European Regulations for Drugs
5.1.5 Asia-Pacific Regulations for Medical Devices
5.2 Reimbursement Scenario
5.2.1 Pricing and Reimbursement Overview
5.2.2 Pricing and Reimbursement for Medical Devices
5.2.3 Pricing and Reimbursement for Pharmaceuticals
5.3 Insurance
5.3.1 Insurance for Diabetic Emergencies

Chapter 6 Impact of Covid-19 on Market

6.1 Overview
6.2 Covid-19 Crisis
6.2.1 Impact on Market for Insulin Drug and Delivery Technologies
6.2.2 Covid-19 Measures

Chapter 7 Market Breakdown by Device Type

7.1 Insulin Delivery Technologies
7.1.1 Syringes
7.1.2 Insulin Pens
7.1.3 Insulin Pumps
7.1.4 Smart Pens
7.1.5 Others

Chapter 8 Market Breakdown by Insulin Type

8.1 Insulin
8.1.1 Structure of Insulin
8.1.2 Insulin Biosynthesis
8.1.3 Insulin Types

Chapter 9 Market Breakdown by Region

9.1 Overview
9.1.1 North America
9.1.2 Europe
9.1.3 Asia-Pacific
9.1.4 Rest of the World

Chapter 10 Analysis of Market Opportunities

10.1 Porter's Five Forces Analysis
10.1.1 Threat of New Entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Degree of Competition

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

12.1 Major Companies

B. Braun Melsungen AG
Becton, Dickinson and Co.
Biocon
Boehringer Ingelheim International GmbH
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Medtronic Inc.
Novo Nordisk A/S
Sanofi
Viatris Inc.
Ypsomed Holding AG
Other Companies
Cequr Simplicity
Debiotech Sa
Emperra GmbH E-Health Technologies
Insulet Corp.
Nanopass Technologies Ltd.
Nipro Medical Corp.
Owen Mumford Ltd.
Tandem Diabetes Care Inc.

Chapter 13 Appendix: Acronyms

List of Tables

Summary Table: Global Market for Insulin Drug and Delivery Technologies, by Device Type, Through 2027
Table 1: Cases of Diabetes Worldwide, by Type
Table 2: Global Prevalence of Diabetes, by Type, Through 2040
Table 3: Global Diabetes Estimates and Projections, 2019-2045
Table 4: History of Insulin Isolation and Development
Table 5: Currently Available Insulin Brands
Table 6: Features of Type 1 and Type 2 Diabetes
Table 7: Strategic Alliances in the Market for Insulin Drug and Delivery Technologies, 2020-2022
Table 8: Insulin Drug and Delivery Technologies Pipeline
Table 9: Global Market for Insulin Drug and Delivery Technologies, by Device Type, Through 2027
Table 10: Advantages and Disadvantages of Syringes
Table 11: Global Market for Syringe Delivery Technologies, by Region, Through 2027
Table 12: Advantages and Disadvantages of Insulin Pens
Table 13: Global Market for Insulin Pen Delivery Technologies, by Region, Through 2027
Table 14: Advantages and Disadvantages of Insulin Pumps
Table 15: Global Market for Insulin Pump Delivery Technologies, by Region, Through 2027
Table 16: Global Market for Smart Insulin Pen Delivery Technologies, by Region, Through 2027
Table 17: Global Market for Other Types of Delivery Technologies, by Region, Through 2027
Table 18: Advantages and Disadvantages of Various Insulin Delivery Systems
Table 19: Types of Insulin and Their Features
Table 20: Global Market for Insulin Drug and Delivery Technologies, by Insulin Type, Through 2027
Table 21: Global Market for Long-acting Insulin, by Region, Through 2027
Table 22: Global Market for Rapid-acting Insulin, by Region, Through 2027
Table 23: Global Market for Intermediate-acting Insulin, by Region, Through 2027
Table 24: Global Market for Short-acting Insulin, by Region, Through 2027
Table 25: Global Market for Premixed Insulin, by Region, Through 2027
Table 26: Global Market for Insulin Drug and Delivery Technologies, by Region, Through 2027
Table 27: Diabetes Estimates in North America, by Country, 2000-2045
Table 28: North American Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
Table 29: Diabetes Estimates in Europe, by Country, 2000-2045
Table 30: European Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
Table 31: Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
Table 32: Asia-Pacific Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
Table 33: Diabetes Estimates in the RoW, by Country, 2000-2045
Table 34: Porter's Five Forces Analysis: Insulin Drug and Delivery Technologies Market
Table 35: B. Braun Melsungen: Insulin Drug and Delivery Product Portfolio
Table 36: BD: Insulin Drug and Delivery Product Portfolio
Table 37: Biocon: Insulin Product Portfolio
Table 38: Biocon: Key Developments, 2020-2021
Table 39: Boehringer Ingelheim: Insulin Product Portfolio
Table 40: Eli Lilly: Insulin Products
Table 41: Eli Lilly: Key Developments, 2020-2021
Table 42: F. Hoffmann-La Roche: Insulin Drug and Delivery Product Portfolio
Table 43: F. Hoffmann-La Roche: Key Developments, 2021
Table 44: Medtronic: Insulin Drug and Delivery Products Portfolio
Table 45: Medtronic: Key Developments, 2020-2021
Table 46: Novo Nordisk: Insulin Drug and Delivery Products Portfolio
Table 47: Novo Nordisk: Key Developments, 2018-2022
Table 48: Sanofi: Insulin Drug and Delivery Products Portfolio
Table 49: Sanofi: Key Developments, 2018-2021
Table 50: Viatris: Insulin Drug and Delivery Products Portfolio
Table 51: Viatris: Key Developments, 2021
Table 52: Ypsomed Holding AG: Insulin Drug and Delivery Products Portfolio
Table 53: Ypsomed Holding AG: Key Developments, 2020-2022
Table 54: Acronyms Used in This Report

List of Figures

Figure A: Timeline of Major Insulin Breakthroughs
Summary Figure A: Global Insulin Drug and Delivery Technologies Market
Summary Figure B: Global Market Shares of Insulin Drug and Delivery Technologies, by Device Type, 2021
Figure 1: Cases of Diabetes Worldwide, by Type
Figure 2: Global Prevalence of Diabetes, by Type, 2018-2040
Figure 3: Medical Device Marketing Process in the U.S.
Figure 4: Global Market Shares of Insulin Delivery Technologies, 2021 and 2027
Figure 5: Global Market for Syringes Delivery Technologies, 2020-2027
Figure 6: Global Market for Insulin Pen Delivery Technologies, 2020-2027
Figure 7: Global Market for Insulin Pump Delivery Technologies, 2020-2027
Figure 8: Global Market for Smart Insulin Pen Delivery Technologies, 2020-2027
Figure 9: Global Market for Other Types of Delivery Technologies, 2020-2027
Figure 10: Global Market Shares of Insulin Drug and Delivery Technologies, by Insulin Type, 2021 and 2027
Figure 11: Global Market for Long-acting Insulin, 2020-2027
Figure 12: Global Market for Rapid-acting Insulin, 2020-2027
Figure 13: Global Market for Intermediate-acting Insulin, 2021-2027
Figure 14: Global Market for Short-acting Insulin, 2020-2027
Figure 15: Global Market for Premixed Insulin, 2020-2027
Figure 16: Snapshot of Global Market for Insulin Drug and Delivery Technologies, 2021
Figure 17: Global Market Shares of Insulin Drug and Delivery Technologies, by Region, 2021
Figure 18: Snapshot of North American Market for Insulin Drug and Delivery Technologies, 2021
Figure 19: North American Market for Insulin Drug and Delivery Technologies, by Country, 2021-2027
Figure 20: Snapshot of European Market for Insulin Drug and Delivery Technologies, 2021
Figure 21: European Market for Insulin Drug and Delivery Technologies, by Country, 2020-2027
Figure 22: European Market Shares of Insulin Drug and Delivery Technologies, by Country, 2021
Figure 23: Snapshot of Asia-Pacific Market for Insulin Drug and Delivery Technologies, 2021
Figure 24: Asia-Pacific Market for Insulin Drug and Delivery Technologies, by Country, 2021-2027
Figure 25: Asia-Pacific Market Shares of Insulin Drug and Delivery Technologies, by Country, 2021
Figure 26: Global Market Shares of Insulin Drug and Delivery Technologies, by Company, 2021
Figure 27: B. Braun Melsungen: Annual Revenue, 2018-2021
Figure 28: B. Braun Melsungen: Revenue Share, by Division, 2021
Figure 29: BD: Annual Revenue, 2018-2021
Figure 30: BD: Revenue Share, by Business Segment, 2021
Figure 31: Boehringer Ingelheim: Annual Revenue, 2018-2021
Figure 32: Boehringer Ingelheim: Revenue Share, by Business Segment, 2021
Figure 33: Eli Lilly: Annual Revenue, 2018-2021
Figure 34: F. Hoffmann-La Roche: Annual Revenue, 2018-2021
Figure 35: F. Hoffmann-La Roche: Revenue Share, by Division, 2021
Figure 36: Medtronic: Annual Revenue, 2018-2021
Figure 37: Medtronic: Revenue Share, by Business Segment, 2021
Figure 38: Novo Nordisk: Annual Revenue, 2018-2021
Figure 39: Novo Nordisk: Revenue Share, by Business Segment, 2021
Figure 40: Sanofi: Annual Revenue, 2018-2021
Figure 41: Sanofi: Revenue Share, by Business Unit, 2021
Figure 42: Viatris: Annual Revenue, 2018-2021
Figure 43: Viatris: Revenue Share, by Product Category, 2020
Figure 44: Ypsomed Holding AG: Annual Revenue, 2018-2021
Figure 45: Ypsomed Holding AG: Revenue Share, by Business Unit, 2021

Executive Summary

Insulin drug and delivery technologies are used to manage type 1 and type 2 diabetes. Expedient insulin delivery devices such as smart pens help diabetes patients optimize blood glucose control and minimize the risk of associated health issues. Advanced insulin delivery devices offer better patient conformity.

The traditional syringes and insulin pumps are being replaced by reusable and disposable insulin pens due to the latter’s portability, greater dosage accuracy, built-in memory, larger dosages and ease of use. There have been no major breakthrough in traditional syringes and pumps.

Major makers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. Key manufacturers of modern insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon and Viatris Inc.

Market growth is attributed to factors such as the increasing incidence of diabetes and novel insulin drug and delivery technologies. The global market for insulin drug and delivery technologies is segmented by device type, insulin type and region.

Companies Mentioned

B. Braun Melsungen AG
Becton, Dickinson and Co.
Biocon
Boehringer Ingelheim International GmbH
Cequr Simplicity
Debiotech Sa
Eli Lilly and Co.
Emperra GmbH E-Health Technologies
F. Hoffmann-La Roche Ltd.
Insulet Corp.
Medtronic Inc.
Nanopass Technologies Ltd.
Nipro Medical Corp.
Novo Nordisk A/S
Owen Mumford Ltd.
Sanofi
Tandem Diabetes Care Inc.
Viatris Inc.
Ypsomed Holding Ag

Table Information

Report Attribute	Details
No. of Pages	120
Published	August 2022
Forecast Period	2022 - 2027
Estimated Market Value ( USD ) in 2022	$ 55.8 Billion
Forecasted Market Value ( USD ) by 2027	$ 88.9 Billion
Compound Annual Growth Rate	9.8%
Regions Covered	Global
No. of Companies Mentioned	19

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5309EUR$5,500USD£4,554GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6370EUR$6,600USD£5,464GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7644EUR$7,920USD£6,557GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9173EUR$9,504USD£7,869GBP

Report Includes

Table of Contents

Executive Summary

Companies Mentioned

Table Information

Related Topics

Related Reports

Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials

Global Insulin Delivery Devices Market by Type (Insulin Pens [Reusable, Disposable], Insulin Pumps (Tethered, Tubeless), Insulin Syringes, Insulin Pen Needles (Standard, Safety)), End User (Hospitals & Clinics, Patients/Homecare) - Forecast to 2028

Human Insulin Market Report by Product Type (Drugs, Delivery Devices), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Retail Stores, and Others), Disease Type (Type I Diabetes, Type II Diabetes), and Region 2024-2032

Insulin Delivery Device - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Human Insulin Drugs and Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029